NASDAQ:MTSR Metsera Q3 2025 Earnings Report Profile Metsera EPS ResultsActual EPS-$1.11Consensus EPS -$0.56Beat/MissMissed by -$0.55One Year Ago EPSN/AMetsera Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AMetsera Announcement DetailsQuarterQ3 2025Date11/12/2025TimeAfter Market ClosesConference Call DateWednesday, November 12, 2025Conference Call Time4:00PM ETConference Call ResourcesQuarterly Report (10-Q)Company ProfilePowered by Earnings DocumentsQuarterly Report(10-Q) Metsera Earnings HeadlinesPfizer Reshapes Portfolio With Seagen And Metsera As COVID Winds ShiftApril 8, 2026 | finance.yahoo.comPfizer Releases Early Obesity Data Showing Up to 12.3% Weight LossFebruary 4, 2026 | finance.yahoo.comI was right about SpaceXJeff Brown predicted Bitcoin before it climbed as high as 52,400%, Tesla before 2,150%, and Nvidia before 32,000%. Now he says SpaceX is shaping up to be the biggest IPO of the decade - and three key milestones just confirmed it. In the past 21 days: SpaceX crossed 10,000 active satellites, Elon filed confidential IPO paperwork with the SEC, and another rocket launched 25 more satellites. Two-thirds of every satellite in orbit now belongs to one company. The public filing could drop any day.May 23 at 1:00 AM | Brownstone Research (Ad)Pfizer Bets On Monthly GLP-1 Obesity Drug To Reshape Growth StoryFebruary 4, 2026 | finance.yahoo.comWhy Pfizer's 2026 guidance miss is 'not a major surprise'December 16, 2025 | msn.comMetsera (MTSR): Evaluating Valuation After Sharp Share Price TurnaroundNovember 14, 2025 | finance.yahoo.comSee More Metsera Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Metsera? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Metsera and other key companies, straight to your email. Email Address About MetseraMetsera (NASDAQ:MTSR), Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o. The company was founded by Clive A. Meanwell in 2022 and is headquartered in New York.View Metsera ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Was Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus?Workday Validates AI Flywheel: Stock Price Recovery BeginsOverextended, e.l.f. Beauty Is Primed to Rebound in Back HalfDeere Beats Q2 Estimates, But Ag Weakness Weighs on OutlookNVIDIA Price Pullback? Don’t Count on It, Business Is AcceleratingMeta Platforms 10% Layoff Raises a Bigger Question About AI SpendingBiogen Stock Slides After Trial Miss, But Analysts Stay Bullish Upcoming Earnings AutoZone (5/26/2026)Marvell Technology (5/27/2026)PDD (5/27/2026)Synopsys (5/27/2026)Bank Of Montreal (5/27/2026)Bank of Nova Scotia (5/27/2026)Salesforce (5/27/2026)Snowflake (5/27/2026)Autodesk (5/28/2026)Costco Wholesale (5/28/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
